首页|乳腺癌中SOCS3与HER2的表达及其临床病理意义

乳腺癌中SOCS3与HER2的表达及其临床病理意义

Expression of SOCS3 and HER2 in breast cancer and their clinicopathological significance

扫码查看
目的 探讨乳腺癌中细胞因子信号转导抑制分子3(SOCS3)与人表皮生长因子受体2(HER2)的蛋白和基因表达及其临床病理意义.方法 选取2019年7月至2024年6月南方医科大学第十附属医院收治的女性乳腺浸润性导管癌病例共计900例,均施行手术切除,且术前均未接受过化疗及放疗.用癌旁正常乳腺组织作为对照,采用盲法对组织行SOCS3和HER2抗体免疫组化染色并判读结果.对HER2蛋白表达水平不确定(2+)的病例,行荧光原位杂交(FISH)实验确认.分析不同Nottingham组织学分级、有无淋巴结转移、不同淋巴结转移数目的乳腺癌组织中SOCS3和HER2表达差异.结果 免疫组化结果显示,SOCS3在乳腺癌组织中的阳性表达率低于癌旁正常组织[5.4%(49/900)比56.8%(511/900)],差异有统计学意义(P<0.05).在乳腺癌组织中HER2表达为2+共计212例、3+共计111例,癌旁正常组织中HER2表达为2+共计91例、3+共计0例.对两组表达为2+的病例行FISH实验,结果乳腺癌组织阳性90例,阴性122例;癌旁正常组织阳性16例,阴性75例.经免疫组化和FISH结果证实,HER2在乳腺癌组织中的阳性表达率高于癌旁正常组织[22.3%(201/900)比1.8%(16/900)],差异有统计学意义(P<0.05).Nottingham组织学分级越高,有淋巴结转移,且多淋巴结转移的乳腺癌中,HER2阳性表达率越高(均P<0.05),SOCS3阳性表达率越低(均P<0.05).结论 乳腺癌中HER2和SOCS3的表达差异与肿瘤Nottingham组织学分级及有无淋巴结转移、淋巴结转移数量相关,HER2的高表达和SOCS3的低表达提示乳腺癌患者预后不良.
Objective To investigate the expression of suppressor of cytokine signaling-3(SOCS-3)and human epidermal growth factor receptor 2(HER2)protein and gene in breast cancer and their clinicopathological significance.Methods A total of 900 female cases of breast invasive ductal carcinoma admitted to the Tenth Affiliated Hospital of Southern Medical University from July 2019 to June 2024 were selected for surgical resection,and none of them had received chemotherapy or radiotherapy before surgery.SOCS3 and HER2 antibody immunohistochemical staining were performed on the normal breast tissues with adjacent cancer as control,and the results were interpreted.Cases with uncertain expression level of HER2 protein(2+)were confirmed by fluorescence in situ hybridization(FISH).The differences of SOCS3 and HER2 expression in breast cancer tissues with different Nottingham histological grade,with or without lymph node metastasis,and with different number of lymph node metastasis were analyzed.Results Immunohis-tochemical results showed that the positive expression rate of SOCS3 in breast cancer tissues was lower than that in adjacent normal tissues[5.4%(49/900)vs 56.8%(511/900)],and the difference was statistically significant(P<0.05).In breast cancer tissues,HER2 expression was 2+in 212 cases,3+in 111 cases,and HER2 expression was 2+in 91 cases and 3+in 0 cases in adjacent normal tissues.Two groups of patients with 2+expression were tested by FISH.The results showed that 90 patients were positive for breast cancer and 122 were negative.There were 16 positive and 75 negative adjacent normal tissues.Immunohistochemistry and FISH results confirmed that the positive expression rate of HER2 in breast cancer tissues was higher than that in adjacent normal tissues[22.3%(201/900)vs 1.8%(16/900)],and the difference was statistically significant(P<0.05).The higher the Nottingham histological grade,the breast cancer with lymph node metastasis and multiple lymph node metastasis,the higher the HER2 positive expression rate(all P<0.05),and the lower the SOCS3 positive expression rate(all P<0.05).Conclusions The difference in the expression of HER2 and SOCS3 in breast cancer is related to the Nottingham histological grade,the presence or absence of lymph node metastasis,and the number of lymph node metastasis.The high expression of HER2 and low expression of SOCS3 suggest poor prognosis of breast cancer patients.

Breast neoplasmsSuppressor of cytokine signaling-3Human epidermal growth factor receptor 2

黄波、黄梓慧、李春瑶

展开 >

南方医科大学第十附属医院(东莞市人民医院)病理科,东莞市临床病理重点实验室,东莞 523000

乳腺肿瘤 细胞因子信号转导抑制因子3 人表皮生长因子受体2

2024

中国医师杂志
中华医学会 湖南省医学会

中国医师杂志

CSTPCD
影响因子:0.876
ISSN:1008-1372
年,卷(期):2024.26(12)